FYERS
Home
/
Stocks
/
Results
/
Eris Lifesciences Results

Eris Lifesciences Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
18%21%23%8%
17%12%17%73%
-12%16%-22%
27%18%17%19%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
ERIS
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,849.9₹447476 Cr3712.0762.82₹11479 Cr
9,602₹254764 Cr87.134.04128.41₹2568 Cr
4,928.5₹189423 Cr86.8516.7297.06₹2163 Cr
1,180.3₹116658 Cr25.859.4262.53₹5040 Cr
1,399₹111484 Cr33.089.7757.87₹3879 Cr
2,026.2₹109943 Cr100.556.829.25₹889 Cr
2,500₹101712 Cr49.7913.7571.08₹1913 Cr
1,200.4₹101005 Cr31.355.3263.99₹4196 Cr
1,716₹99253 Cr26.7317.9596.84₹3505 Cr
2,100.7₹96031 Cr17.3730.95154.35₹5333 Cr
1,275₹17618 Cr27.3610.2766.67₹620 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012
———————————————
₹14 Cr₹14 Cr₹14 Cr₹14 Cr₹14 Cr₹14 Cr₹14 Cr₹14 Cr₹14 Cr₹14 Cr₹14 L₹14 L₹14 L₹14 L₹14 L
₹14 Cr₹10 Cr₹5 Cr₹3 Cr₹2 Cr₹4 Cr₹3 Cr₹1 Cr₹0₹0₹0₹0₹0₹0₹0
₹3875 Cr₹2831 Cr₹2568 Cr₹2180 Cr₹1893 Cr₹1559 Cr₹1280 Cr₹1136 Cr₹848 Cr₹553 Cr₹299 Cr₹266 Cr₹177 Cr₹106 Cr₹48 Cr
₹3875 Cr₹2831 Cr₹2568 Cr₹2180 Cr₹1893 Cr₹1559 Cr₹1280 Cr₹1136 Cr₹848 Cr₹553 Cr₹299 Cr₹266 Cr₹177 Cr₹106 Cr₹48 Cr
₹3903 Cr₹2854 Cr₹2586 Cr₹2196 Cr₹1908 Cr₹1576 Cr₹1296 Cr₹1151 Cr₹861 Cr₹567 Cr₹300 Cr₹266 Cr₹177 Cr₹106 Cr₹48 Cr
-₹7 Cr₹417 Cr₹636 Cr₹25 Cr-₹11 L₹20,000₹0₹18 Cr₹25 Cr₹24 Cr₹3 Cr₹4 Cr₹4 Cr₹5 Cr₹5 Cr
₹956 Cr₹1738 Cr₹655 Cr₹644 Cr₹45 Cr₹0₹0₹29 L₹274 Cr₹49 L₹0₹50 L₹0₹56 L₹3 Cr
₹62 Cr₹229 Cr₹227 Cr-₹16 Cr-₹197 Cr-₹151 Cr-₹120 Cr-₹93 Cr-₹48 Cr-₹15 Cr-₹6 Cr-₹3 Cr-₹21 L-₹26 L₹2 L
₹45 Cr₹55 Cr₹45 Cr₹57 Cr₹41 Cr₹11 Cr₹15 Cr₹8 Cr₹3 Cr₹4 Cr₹2 Cr₹1 Cr₹1 Cr₹2 Cr₹2 Cr
₹87 Cr₹79 Cr₹53 Cr₹45 Cr₹32 Cr₹31 Cr₹26 Cr₹19 Cr₹19 Cr₹23 Cr₹23 Cr₹20 Cr₹17 Cr₹15 Cr₹9 Cr
₹1150 Cr₹2101 Cr₹979 Cr₹730 Cr-₹79 Cr-₹109 Cr-₹80 Cr-₹65 Cr₹248 Cr₹12 Cr₹20 Cr₹19 Cr₹18 Cr₹17 Cr₹14 Cr
———————————————
₹330 Cr₹332 Cr₹219 Cr₹125 Cr₹118 Cr₹103 Cr₹100 Cr₹84 Cr₹91 Cr₹39 Cr₹25 Cr₹37 Cr₹37 Cr₹22 Cr₹18 Cr
₹1178 Cr₹534 Cr₹900 Cr₹190 Cr₹36 Cr₹29 Cr₹27 Cr₹199 Cr₹115 Cr₹14 Cr₹10 Cr₹8 Cr₹15 Cr₹9 Cr₹5 Cr
₹454 Cr₹397 Cr₹1311 Cr₹55 Cr₹1 L₹1 L₹0₹0₹0₹0₹0₹0₹0₹0₹0
₹240 Cr₹230 Cr₹179 Cr₹151 Cr₹130 Cr₹104 Cr₹93 Cr₹95 Cr₹88 Cr₹77 Cr₹35 Cr₹21 Cr₹19 Cr₹13 Cr₹12 Cr
₹2201 Cr₹1493 Cr₹2609 Cr₹521 Cr₹283 Cr₹235 Cr₹220 Cr₹377 Cr₹294 Cr₹129 Cr₹69 Cr₹65 Cr₹71 Cr₹44 Cr₹35 Cr
₹7247 Cr₹6866 Cr₹6810 Cr₹3472 Cr₹2113 Cr₹1703 Cr₹1437 Cr₹1481 Cr₹1428 Cr₹732 Cr₹392 Cr₹354 Cr₹270 Cr₹172 Cr₹102 Cr
₹52 Cr₹52 Cr₹54 Cr₹28 Cr₹25 Cr₹20 Cr₹17 Cr₹17 Cr₹14 Cr₹13 Cr₹59 L₹90 L₹59 L₹5 L₹5 L
₹2310 Cr₹2422 Cr₹2735 Cr₹830 Cr₹45 Cr₹1 L₹0₹176 Cr₹377 Cr₹65 L₹50 L₹1 Cr₹53 L₹3 Cr₹5 Cr
———————————————
₹6162 Cr₹6061 Cr₹4773 Cr₹2843 Cr₹1092 Cr₹1006 Cr₹984 Cr₹838 Cr₹820 Cr₹254 Cr₹123 Cr₹104 Cr₹91 Cr₹39 Cr₹32 Cr
₹974 Cr₹754 Cr₹454 Cr₹275 Cr₹174 Cr₹152 Cr₹109 Cr₹78 Cr₹48 Cr₹23 Cr₹52 Cr₹32 Cr₹17 Cr₹12 Cr₹9 Cr
₹5188 Cr₹5306 Cr₹4319 Cr₹2568 Cr₹918 Cr₹854 Cr₹875 Cr₹761 Cr₹771 Cr₹232 Cr₹71 Cr₹72 Cr₹75 Cr₹27 Cr₹23 Cr
₹171 Cr₹67 Cr₹19 Cr₹21 Cr₹24 Cr₹0₹0₹75 L₹0₹7 L₹0₹0₹0₹0₹0
₹62 Cr₹62 Cr₹16 Cr₹7 Cr₹421 Cr₹244 Cr₹3 Cr₹41 Cr₹272 Cr₹213 Cr₹63 Cr₹97 Cr₹17 Cr₹70,000₹60,000
₹62 Cr₹62 Cr₹16 Cr₹7 Cr₹421 Cr₹244 Cr₹3 Cr₹41 Cr₹272 Cr₹213 Cr₹63 Cr₹97 Cr₹17 Cr₹70,000₹60,000
₹152 Cr₹88 Cr₹70 Cr₹25 Cr₹36 Cr₹26 Cr₹16 Cr₹17 Cr₹12 Cr₹13 Cr₹35 Cr₹21 Cr₹23 Cr₹18 Cr₹9 Cr
₹10 Cr₹7 Cr₹7 Cr₹7 Cr₹0₹42 Cr₹3 Cr₹6 Cr₹6 Cr₹5 Cr₹0₹0₹0₹0₹0
₹5583 Cr₹5531 Cr₹4431 Cr₹2629 Cr₹1402 Cr₹1167 Cr₹902 Cr₹827 Cr₹1061 Cr₹463 Cr₹169 Cr₹190 Cr₹115 Cr₹45 Cr₹33 Cr
———————————————
₹0₹5 Cr₹0₹30 Cr₹100 Cr₹50 Cr₹75 Cr₹315 Cr₹94 Cr₹90 Cr₹127 Cr₹69 Cr₹67 Cr₹47 Cr₹13 Cr
₹437 Cr₹335 Cr₹189 Cr₹131 Cr₹118 Cr₹94 Cr₹69 Cr₹83 Cr₹65 Cr₹56 Cr₹48 Cr₹58 Cr₹45 Cr₹43 Cr₹23 Cr
₹680 Cr₹459 Cr₹422 Cr₹293 Cr₹161 Cr₹140 Cr₹157 Cr₹84 Cr₹67 Cr₹49 Cr₹25 Cr₹24 Cr₹22 Cr₹17 Cr₹14 Cr
₹67 Cr₹223 Cr₹1401 Cr₹58 Cr₹52 Cr₹38 Cr₹67 Cr₹8 Cr₹11 Cr₹2 Cr₹10 Cr₹6 Cr₹7 Cr₹5 Cr₹9 Cr
₹44 Cr₹26 Cr₹32 Cr₹22 Cr₹24 Cr₹36 Cr₹55 Cr₹58 Cr₹44 Cr₹4 Cr₹2 Cr₹2 Cr₹3 Cr₹89 L₹40 L
₹435 Cr₹287 Cr₹335 Cr₹308 Cr₹256 Cr₹176 Cr₹111 Cr₹107 Cr₹86 Cr₹68 Cr₹10 Cr₹5 Cr₹11 Cr₹14 Cr₹9 Cr
₹1664 Cr₹1334 Cr₹2379 Cr₹843 Cr₹711 Cr₹536 Cr₹535 Cr₹653 Cr₹367 Cr₹269 Cr₹222 Cr₹163 Cr₹155 Cr₹126 Cr₹69 Cr
-₹537 Cr-₹158 Cr-₹230 Cr₹321 Cr₹428 Cr₹300 Cr₹315 Cr₹276 Cr₹73 Cr₹140 Cr₹153 Cr₹98 Cr₹84 Cr₹83 Cr₹34 Cr
₹7247 Cr₹6866 Cr₹6810 Cr₹3472 Cr₹2113 Cr₹1703 Cr₹1437 Cr₹1481 Cr₹1428 Cr₹732 Cr₹392 Cr₹354 Cr₹270 Cr₹172 Cr₹102 Cr
₹281₹209₹190₹161₹140₹116₹95₹84₹63₹41₹21,712₹19,279₹12,818₹7,688₹3,470
₹281₹209₹190₹161₹140₹116₹95₹84₹63₹41₹22₹19₹13₹8₹3

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012
₹639 Cr₹489 Cr₹431 Cr₹405 Cr₹442 Cr₹394 Cr₹331 Cr₹317 Cr₹312 Cr₹270 Cr₹154 Cr₹109 Cr₹98 Cr₹83 Cr₹55 Cr
₹482 Cr₹548 Cr₹254 Cr₹140 Cr₹49 Cr₹44 Cr₹44 Cr₹31 Cr₹14 Cr-₹65 L₹20 Cr₹12 Cr₹69 L₹7 Cr₹3 Cr
-₹458 Cr₹126 Cr-₹99 Cr-₹176 Cr-₹30 Cr₹5 Cr-₹53 Cr-₹53 Cr-₹22 Cr-₹16 Cr-₹8 Cr-₹8 Cr₹21 Cr-₹16 Cr-₹11 Cr
₹662 Cr₹1163 Cr₹587 Cr₹369 Cr₹462 Cr₹444 Cr₹323 Cr₹295 Cr₹304 Cr₹253 Cr₹166 Cr₹113 Cr₹120 Cr₹74 Cr₹48 Cr
₹538 Cr₹1065 Cr₹486 Cr₹292 Cr₹378 Cr₹375 Cr₹271 Cr₹223 Cr₹235 Cr₹200 Cr₹131 Cr₹90 Cr₹90 Cr₹38 Cr₹30 Cr
-₹369 Cr-₹80 Cr-₹1855 Cr-₹982 Cr-₹320 Cr-₹323 Cr₹123 Cr-₹5 Cr-₹590 Cr-₹184 Cr-₹44 Cr-₹92 Cr-₹83 Cr-₹36 Cr-₹19 Cr
-₹314 Cr-₹881 Cr₹1380 Cr₹688 Cr-₹45 Cr-₹82 Cr-₹335 Cr-₹221 Cr₹363 Cr-₹24 Cr-₹84 Cr₹46 L-₹2 Cr-₹3 Cr-₹10 Cr
-₹145 Cr₹104 Cr₹11 Cr-₹2 Cr₹14 Cr-₹30 Cr₹60 Cr-₹3 Cr₹8 Cr-₹8 Cr₹4 Cr-₹2 Cr₹5 Cr-₹77 L₹100 L
₹200 Cr₹94 Cr₹56 Cr₹51 Cr₹37 Cr₹67 Cr₹8 Cr₹11 Cr₹2 Cr₹9 Cr₹5 Cr₹7 Cr₹2 Cr₹3 Cr₹2 Cr
₹0₹2 Cr₹27 Cr₹7 Cr₹0₹0₹0₹0₹52 L₹1 Cr₹0₹0₹0₹0₹0
₹55 Cr₹200 Cr₹94 Cr₹56 Cr₹51 Cr₹37 Cr₹67 Cr₹8 Cr₹11 Cr₹2 Cr₹9 Cr₹5 Cr₹7 Cr₹2 Cr₹3 Cr

Fundamental Ratios

Consolidated
Standalone

Share Price Live Stats

Open (₹)1,266.00
Volume (₹)47,023.00
High (₹)1,284.10
Upper Circuit1,523.80
Low (₹)1,264.50
Lower Circuit1,016.00
Prev Close1,269.90
52W High (₹)1,740.00
Price1,275.00
52W Low (₹)1,200.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)17617.70 Cr
Div. Yield (%)0.00
PE Ratio27.36
Debt to Equity0.59
Price to Book4.62
Book Value280.75
EPS (TTM)46.41
Face Value1.00
ROE (%)19.23

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
ERISNSE
LTP
1W Low
1W High
Market cap (₹)
1849.9+12.6 (0.69%)
1832.20
1891.50
4,47,476Cr
9602+227 (2.42%)
9312.50
9740
2,54,764Cr
4928.5+88.5 (1.83%)
4848.50
5010
1,89,423Cr
1180.3+20.3 (1.75%)
1152.10
1190.60
1,16,658Cr
1399+4.5 (0.32%)
1364.50
1419
1,11,484Cr
2026.2+72.2 (3.69%)
1963.80
2055.30
1,09,943Cr
2500+199.3 (8.66%)
2303
2504.30
1,01,712Cr
1200.4+15.4 (1.30%)
1185
1222
1,01,005Cr
1716-18 (-1.04%)
1689.30
1740
99,253Cr
2100.7+17.7 (0.85%)
2080
2135
96,031Cr
1275-46.3 (-3.50%)
1263.60
1330.90
17,618Cr

Eris Lifesciences Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹298.61Cr; with other income of ₹2.39Cr, profit before interest and tax came to ₹226.54Cr. Interest expense was ₹46.65Cr; PBT before exceptional items stood at ₹179.89Cr. Cost mix (full year): raw materials ₹749.46Cr; employee cost ₹505.09Cr; depreciation ₹72.07Cr; other expenses ₹577.03Cr. Basis: consolidated annual results.

Eris Lifesciences Ltd Quaterly Results Key Takeaways

Eris Lifesciences Ltd reported ₹873.25Cr total income from operations in Jun 2026, softer than ₹756.56Cr in Mar 2026 but higher than ₹773Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹298.61Cr; with other income of ₹2.39Cr, profit before interest and tax came to ₹226.54Cr. Interest expense was ₹46.65Cr, taking profit before tax to ₹179.89Cr. After tax of ₹36.17Cr, profit after tax stood at ₹143.72Cr (vs ₹280.3Cr in Mar 2026 and ₹124.21Cr in Jun 2025).